PRAX Receives FDA Breakthrough
Praxis Precision Medicines receives FDA Breakthrough Therapy Designation for Elsunersen to treat seizures associated with SCN2A developmental and epileptic encephalopathy
PRAX - Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants